ClinicalTrials.gg
CompletedNCT02318758TDE-PH-125Updated Mar 24, 2015

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

A Phase 1 interventional study of UT-15C and ethanol in Healthy, sponsored by United Therapeutics. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-24.

Sponsored by United Therapeutics · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

A study to assess the interaction of acohol and oral treprostinil.

Read the detailed description

This study will compare the effects of ethanol on the PKs of a 1 mg dose of UT-15C in healthy volunteers to determine the in vivo effects of ethanol, including the timing of ethanol consumption in relation to UT-15C ingestion.

This is an open-label, randomized, single-center, four-way (period), crossover study in which 28 healthy volunteers will receive a single 1 mg oral dose of UT-15C and/or ethanol. Eligible subjects will be randomly assigned to one of four treatment sequences such that all subjects will receive all four sequences in a pre-specified order.

02

Conditions studied

  • Healthy

Keywords

  • This is a healthy volunteer study.
03

In context

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily gives to participate in the study.
  2. Women of child bearing potential includes any female who has experienced menarche and who has not undergone successful surgical sterilization. Women of must practice true abstinence from intercourse when it is in line with their preferred and usual lifestyle, or use two different forms of highly effective for the duration of the study, and for at least 30 days after discontinuing study medication. Medically acceptable forms of effective contraception include: (1) approved hormonal contraceptives (such as birth control pills), (2) barrier methods used with a spermicide, (3) an intrauterine device, or (4) partner vasectomy. For women of childbearing potential, a negative urine pregnancy test is required at Screening and Baseline prior to initiating study medication.
  3. The subject, if male, must use a condom during the length of the study, and for at least 48 hours after discontinuing study medication.
  4. Healthy male and female subjects aged 21-55 years of age at the time of signing the informed consent.
  5. Weight between 55 and 100 kg, with a between 19.0-29.9 kg/m2, inclusive for female subjects and weight between 55 and 120 kg, with a BMI between 19.0-32.0 kg/m2, inclusive for male subjects.
  6. Regular consumption of ethanol with no recent changes in pattern of consumption
  7. In the opinion of the Principal Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion criteria

Exclusion Criteria:

  1. The subject is pregnant or lactating.
  2. Subject has any abnormality identified during the screening physical examination, 12-lead , or laboratory examinations.
  3. Subject has a history of anaphylaxis, a previous documented reaction, or a clinically significant idiosyncratic reaction to any drug.
  4. Subject has a clinically significant history of neurological, cardiovascular, respiratory, endocrine, hematological, hepatic, renal, gastrointestinal, genitourinary, pulmonary, and/or musculoskeletal disease; glaucoma; a psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
  5. Subject has a history of postural hypotension, or unexplained syncope.
  6. Subject has a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.
  7. Subject has a pulse rate that is greater than 90 bpm after sitting at rest for 5 minutes at Screening or Baseline.
  8. Subject has a blood pressure that is greater than 150 mmHg systolic or 90 mmHg diastolic at Screening or Baseline.
  9. Subject has a predisposing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs.
  10. Subject has tested positive at the screening visit for infection, , or the antibody.
  11. Subject currently uses tobacco products or has a history of tobacco use within two months prior to Baseline.
  12. Subject has a history of ethanol abuse or a history of or current impairment of organ function reasonably related to ethanol abuse.
  13. Subject has a history of or current evidence of abuse of licit or illicit drugs, including a positive urine screen for drugs of abuse at Screening or Baseline.
  14. Subject has a history of abnormal bleeding tendencies.
  15. Subject has donated blood or plasma or has lost a significant volume of blood within four weeks prior to Baseline.
  16. Subject has clinically significant abnormal laboratory values in the opinion of the treating Investigator.
  17. Subject has participated in a research study within the last 30 days.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Comparison 1

    UT-15C 1 mg alone

    Drug: UT-15C

  • Active comparator
    Comparison 2

    UT-15C 1 mg plus ethanol (simultaneously)

    Drug: UT-15C · Other: ethanol

  • Active comparator
    Comparison 3

    UT-15C 1 mg administered 1 hour before ethanol

    Drug: UT-15C · Other: ethanol

  • Active comparator
    Comparison 4

    UT-15C 1 mg administered 1 hour after ethanol

    Drug: UT-15C · Other: ethanol

Interventions

  • DrugUT-15C

    sustained release oral treprostinil

    Also known as: Oral treprostinil

  • Otherethanol

    Absolut 100 vodka

    Also known as: alcohol

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of oral treprostinil (Cmax)

    Time frame: Subjects will be enrolled for 24 days

Secondary outcomes

  1. Safety and tolerability via laboratory values, collection of adverse events, vital signs and electrocardiogram.

    Time frame: Subjects will be enrolled for 24 days

07

Study locations

1 site
  • PPD International
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2014
First posted
Dec 17, 2014
Start
Sep 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Last update
Mar 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02318758
Responsible party
Sponsor
First posted
Dec 17, 2014
Start date
Sep 2014
Primary completion
Oct 2014
Completion
Dec 2014
Last update
Mar 24, 2015

Study contacts

Aziz Laurent, MD
principal investigator · PPD DEVELOPMENT, LP

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion